1. Scrip
  2. >>Business

Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology

 
• By Jessica Merrill

Bind has agreed to sell all of its assets to Pfizer for $19.75m after filing for bankruptcy in May. An auction is scheduled for July 25 if other bidders come forward.

Pfizer Inc. is poised to buy the Cambridge, Mass.-based nanoparticle technology company Bind Therapeutics Inc. for $19.75m, with the intention of applying Bind’s technology to its immuno-oncology portfolio.

The company has cash to invest in M&A after its planned $160bn merger with Allergan PLC collapsed earlier this year. (Also see "Pfizer-Allergan Merger: The End Is Nigh " - Scrip, 6 April, 2016.) Pfizer’s only other significant M&A news since that deal fell through in April is the acquisition of Anacor Pharmaceuticals Inc. for $5.2bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

More from Business